Mochida Pharmaceutical Co., Ltd. · TSE:4534
Mochida Pharmaceutical — FY2023 Earnings Presentation
31 slides from Mochida Pharmaceutical's earnings presentation, May 16, 2024
Slide 1: FY2023 Financial Results Presentation
FY2023 Financial Results Presentation May 16, 2024 Mochida Pharmaceutical Co., Ltd.
Slide 2: Disclaimer (1/2)
Disclaimer (1/2) This material is an English translation of the Financial Results Presentation for the Fiscal Year 2023 to be issued on May 16, 2024 in Japanese, and the Japanese presentation is given priority regarding content and interpretation. The information provided in this material contai
Slide 3: Disclaimer (2/2)
Disclaimer (2/2) Approved products contain risks relating to manufacturing and marketing which include, but not are limited to, situations in which the Company may face deficiencies in manufacturing capacity needed to meet demand, difficulties in securing the supplies of raw materials, and demand
Slide 4: Agenda
Agenda • FY2023 Overview • FY2024 Forecast • Progress on the 22-24 Medium-Term Management Plan FY2023 Financial Results Presentation 4
Slide 5: FY2023 Overview
FY2023 Overview FY2023 Financial Results Presentation 5
Slide 6: Business environment
Business environment The ever off-year NHI drug price list revision in April 2023. Decrease in drug prices (The drug price revision rate for all listed products was in the -8% range.) Increase in import prices of active pharmaceutical ingredients and pharmaceutical formulations due to deprecia
Slide 7: Summary of FY2023 (1/2)
Summary of FY2023 (1/2) Consolidated Financial Results 103.2 102.8 Net sales declined Net sales declined due to NHI drug price revisions and declining sales of long-listed products such as Lexapro®, which offset the growth in sales of new drugs and new products. 【New products】 Net sales • Treprost
Slide 8: Summary of FY2023 (2/2)
Summary of FY2023 (2/2) Progress in development pipeline Ethical drug • Filed: ACT-541468 (daridorexant) • Filed (Additional indication): Treprost® Inhalation Solution Medical device • Filed: dMD-001 • Initiation of therapeutic confirmatory study: dMD-003 • Filed (510(k)): Nerve Cuff Business al
Slide 9: Consolidated operating results
Consolidated operating results (Millions of yen) FY2023 Forecasts FY2022 FY2023 Y o Y value (announced on May 15, 2023) (Y o Y changes) (Y o Y changes) (Y o Y changes) 103,261 102,885 104,000 Net sales -375 (-6.3％) (-0.4％) (0.7％) 8,507 5,802 8,500 Operating profit -2,705 (-40.9％) (-31.8％) (-0.1％) Ra
Slide 10: Net sales by business
Net sales by business (Millions of yen) FY2023 Forecasts FY2022 FY2023 Y o Y value (announced on May 15, 2023) (Y o Y changes) (Y o Y changes) (Y o Y changes) 103,261 102,885 104,000 Net sales -375 (-6.3％) (-0.4％) (0.7％) Pharmaceuticals 97,340 96,455 97,700 business (-6.8％) (-0.9％) -885 (0.3％) Healt
Slide 11: Sales of major products (1/2)
Sales of major products (1/2) （Billions of yen） FY2023 Products FY2022 YoY Sales Value Ratio ■ New drugs Treatment of ulcerative colitis Lialda® 13.5 14.5 0.9 7％ Treatment for chronic constipation Goofice® 6.9 7.7 0.8 12％ Treatment for chronic constipation Movicol® 5.4 5.9 0.4 8％ Gout and hyperurice
Slide 12: Sales of major products (2/2)
Sales of major products (2/2) （Billions of yen） FY2023 Products FY2022 YoY Sales Value Ratio ■ Long-listed products Drug for hyperlipidemia and Epadel 7.1 7.4 0.2 4％ arteriosclerosis obliterans Antidepressant Lexapro® 11.0 5.2 -5.8 -53％ Calcium channel blocker with a long-acting hypotensive effect A
Slide 13: Consolidated financial statements
Consolidated financial statements (Millions of yen) Major fluctuation factors (Millions of yen) YoY FY2022 FY2023 YoY value （As of March 31, 2023） （As of March 31, 2024） value Total assets 158,831 158,800 -31 Total current Cash and time deposits -13,720 assets 117,379 116,662 -717 Accounts receivabl
Slide 14: FY2024 Forecast
FY2024 Forecast FY2023 Financial Results Presentation 14
Slide 15: Plan for FY2024
Plan for FY2024 Pharmaceuticals • Focusing on targeted areas with a focus on new drugs Further growth of Goofice® and Urece® etc. Expanding Omvoh® and Cortiment® by focus on the gastroenterology Aiming to launch ACT-541468 (daridorexant) • Promoting enhancement of development pipeline • Focu
Slide 16: Consolidated financial result forecasts
Consolidated financial result forecasts (Millions of yen) FY2022 FY2023 FY2024 Forecasts (Y o Y changes) (Y o Y changes) (Y o Y changes) 103,261 102,885 106,000 Net sales (-6.3％) (-0.4％) (3.0％) 8,507 5,802 7,500 Operating profit (-40.9％) (-31.8％) (29.3％) Ratio of operating 8.2％ 5.6％ 7.1％ profit to n
Slide 17: Forecasts by business
Forecasts by business (Millions of yen) FY2022 FY2023 FY2024 Forecasts (Y o Y changes) (Y o Y changes) (Y o Y changes) 103,261 102,885 106,000 Net sales (-6.3％) (-0.4％) (3.0％) Pharmaceuticals 97,340 96,455 99,180 business (-6.8％) (-0.9％) (2.8％) Healthcare 5,920 6,430 6,820 business (3.3％) (8.6％) (6.
Slide 18: Forecasts of major products (1/2)
Forecasts of major products (1/2) （Billions of yen） FY2024 Forecasts Products FY2023 YoY Sales Value Ratio ■ New drugs Treatment of ulcerative colitis Lialda® 14.5 14.6 0.1 1％ Treatment for chronic constipation Goofice® 7.7 9.0 1.2 16％ Treatment for chronic constipation Movicol® 5.9 6.0 0.0 1％ Gout
Slide 19: Forecasts of major products (2/2)
Forecasts of major products (2/2) （Billions of yen） FY2024 Forecasts Products FY2023 YoY Sales Value Ratio ■ Long-listed products Drug for hyperlipidemia and Epadel 7.4 6.5 -0.8 -12％ arteriosclerosis obliterans Antidepressant Lexapro® 5.2 3.7 -1.5 -29％ Calcium channel blocker with a long-acting hypo
Slide 20: Development Pipeline: Ethical drugs
Development Pipeline: Ethical drugs Stage Development Remarks Indications code Phase Phase ＜Development country＞ Filed Approved Ⅱ Ⅲ Co-development with Nxera ACT-541468 Insomnia Pharma Japan Co., Ltd. <Japan> Pulmonary hypertension associated Licensed-in from United with interstitial lung disease or
Slide 21: Development Pipeline: Medical devices
Development Pipeline: Medical devices Stage Development code Intended use Remarks Therapeutic Therapeutic or Common name or indications ＜Development country＞ exploratory confirmatory Filed Approved study study Articular cartilage In-house development dMD-001 lesion <Japan> Cavernous nerve In-house d
Slide 22: Progress on the 22-24 Medium-Term Management Plan
Progress on the 22-24 Medium-Term Management Plan FY2023 Financial Results Presentation 22
Slide 23: Vision for 2031 and 22-24 Medium-Term Management Plan (MTP)
Vision for 2031 and 22-24 Medium-Term Management Plan (MTP) Vision for 2031 As a life and healthcare group, take on the challenge of addressing unmet medical and health needs by incorporating new drug discovery modalities that are expected to grow in the future. 22-24 25-27 28-30 Pharmaceuticals MTP
Slide 24: Maximization of profits in targeted areas with a focus on new drugs
Maximization of profits in targeted areas with a focus on new drugs FY2023 FY2024 New products Maximizing the sales of new drugs • Omvoh® • Continuous growth of Goofice® and Urece® • Cortiment® • Expanding the sales of Omvoh ® and • Treprost® Inhalation Solution Pharma Cortiment ® by focusing on
Slide 25: Continuous investment in growth to realize the Vision for 2031 (1/3)
Continuous investment in growth to realize the “Vision for 2031” (1/3) FY2023 FY2024 Pharma Consideration and negotiations to Promoting enhancement of development ceuticals strengthen the development pipeline pipeline business Filed: dMD-001 Aiming to launch dMD-001 Filed (510(k)): Nerve C
Slide 26: dMD-001
dMD-001 A medical device primarily composed of sodium alginate solution Femur Properties of alginate Cartilage • A naturally occurring polysaccharide unique to seaweed • When dissolved in water, it forms a highly viscous solution that gels when calcium ions are added Meniscus Clinical trial Fi
Slide 27: Continuous investment in growth to realize the Vision for 2031 (2/3)
Continuous investment in growth to realize the “Vision for 2031” (2/3) FY2023 FY2024 Continuous growth of the Collage Repair series and the Collage Furfur series Aiming to improve brand image and expanding Healthcare New products business scale by reviewing product lineup and business • Collag
Slide 28: Continuous investment in growth to realize the Vision for 2031 (3/3)
Continuous investment in growth to realize the “Vision for 2031” (3/3) FY2023 FY2024 Promoted highly purified EPA drugs mainly Establishing International Business in Asia Development Department in April, 2024 • Thailand: Achieved favorable sales Promoting Highly purified EPA projects • Vietnam
Slide 29: Strengthening of the corporate organization to create innovation and improve productivity
Strengthening of the corporate organization to create innovation and improve productivity FY2023 FY2024 Initiation of operation of personnel and wage systems that allows diverse human resources can participate Institutio Implementation of new customer Full utilization of the systems and instit
Slide 30: Shareholder returns
Shareholder returns Maintaining a stable dividends while enhancing internal reserves for future business development Policy Maintaining the dividend of at least 80 yen per share during the 22- 24 MTP period （yen） FY2022 FY2023 FY2024 Forecasts Annual dividends 80.00 80.00 80.00 per share (Interi
Slide 31: FY2023 Financial Results Presentation
FY2023 Financial Results Presentation 31
Mochida Pharmaceutical — FY2023 Earnings Presentation on 6ix